hapabapa/iStock Editorial by way of Getty Pictures
Gross sales from Eli Lilly’s (NYSE:LLY) newly authorised weight reduction remedy, Zepbound, might attain $4.1B by 2031 within the U.S., a current report from information analytics agency GlobalData signifies.
In accordance with the report, that’s about half the extent of rival Novo Nordisk’s (NVO) weight reduction remedy Wegovy might generate by that 12 months.
Each Wegovy and Zepbound additionally indicated for Kind 2 diabetes, as Ozempic and Mounjaro generated $8.6B and $482.5M in international gross sales in 2022, respectively.
GlobalData’s newest forecast comes shut on the heels of FDA approval of LLY’s GLP-1 receptor agonist, often known as tirzepatide, for continual weight administration in adults.
The Indiana-based pharma large plans to launch the product earlier than year-end at a month-to-month listing value of about $1,060, with a 20% low cost to Wegovy, often known as semaglutide. In October, GlobalData projected Wegovy gross sales within the U.S. might attain $8.1B by 2031.
“Zepbound is Eli Lilly’s first drug which is indicated for weight problems, and its arrival to the weight problems house is ready to lift the competitors for Novo Nordisk’s Wegovy (semaglutide) as a gold-standard remedy,” Sara Reci, Senior Pharma Analyst at GlobalData, famous.
Regardless of hurdles to their uptake, comparable to lack of insurance coverage protection and manufacturing constraints, pharma’s deal with discovering extra efficacious weight reduction medicine will propel this indication to a $27.6B worth within the U.S. by 2031, GlobalData stated, citing a patient-based forecast.
Different main drugmakers growing weight-loss medicine embody Pfizer (PFE) and Amgen (AMGN). Final week, AstraZeneca (AZN) inked a a deal price as much as $2B with China-based biotech Eccogene to develop an oral, once-daily GLP-1 receptor agonist for circumstances together with weight reduction.
“Nonetheless, it’s anticipated that the competitors between Eli Lilly and Novo Nordisk to win affected person shares for this indication will likely be fierce and one to be careful for,” GlobalData’s Reci added.
